帕米膦酸二钠联合复方苦参注射液对非小细胞肺癌患者外周血CEA、CA125、IL-2、IL-4和T淋巴细胞亚群的影响  

Impacts of pamidronate disodium combined with compound kushen injection on CEA,CA125,IL-2,IL-4 and T lymphocyte subsets in peripheral blood of patients with non-small cell lung cancer

作　　者：毛玲[1] 陈超[2] MAO Ling;CHEN Chao(Department of Oncology,Jurong People Hospital,Jiangsu,Jurong 212400,China;Department of Chest Surgery,Jurong People Hospital,Jiangsu,Jurong 212400,China)

机构地区：[1]句容市人民医院肿瘤内科,江苏句容212400 [2]句容市人民医院胸外科,江苏句容212400

出　　处：《中国医药科学》2023年第3期13-16,30,共5页China Medicine And Pharmacy

基　　金：江苏省句容市民生科技计划项目(SF2019735549);江苏大学临床医学科技发展基金项目(JLY20180141)

摘　　要：目的探讨帕米膦酸二钠单药及联合复方苦参注射液治疗非小细胞肺癌,对其外周血癌胚抗原(CEA)、糖类抗原125(CA125)、血清细胞因子白介素-2(IL-2)、白介素-4(IL-4)及T淋巴细胞亚群的影响。方法选取2018年1月至2022年3月句容市人民医院收治的非小细胞肺癌患者50例。采取分别抽样法分组,即单药帕米膦酸二钠干预的单药组(n=25)和帕米膦酸二钠联合复方苦参注射液干预的联合治疗组(n=25)。观察两组临床指标。结果联合治疗组的客观缓解率、临床获益率及生活质量均高于单药组,差异有统计学意义(P<0.05);联合治疗组的CEA、CA125水平低于单药组,差异有统计学意义(P<0.05);联合治疗组IL-2水平高于单药组、IL-4水平低于单药组,差异有统计学意义(P<0.05);联合治疗组CD4^(+)、CD4^(+)/CD8^(+)水平高于单药组,差异有统计学意义(P<0.05);联合治疗组的不良反应总发生率低于单药组,差异有统计学意义(P<0.05)。结论帕米膦酸二钠联合复方苦参注射液治疗非小细胞肺癌,可调节炎性因子水平,增强抗肿瘤活性及免疫功能,减轻炎性反应,不良反应发生率低。Objective To investigate the impacts of single pamidronate disodium and pamidronate disodium combined with compound kushen injection on carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125),interleukin-2(IL-2),interleukin-4(IL-4)and T lymphocyte subsets in peripheral blood of patients with non-small cell lung cancer.Methods A total of 50 patients with non-small cell lung cancer admitted to and treated in Jurong People Hospital from January 2018 to March 2022 were selected.They were divided into the single treatment group(n=25,intervened by single pamidronate disodium)and the combined treatment group(n=25,intervened by pamidronate disodium combined with compound kushen injection)according to the separate sampling method.Observe the clinical indicators of the two groups.Results The objective response rate,clinical benefits,and quality of life of the combined treatment group were all higher than those of the single treatment group,with statistically significant differences(P<0.05).The levels of CEA and CA125 in the combined treatment group were lower than those in the single treatment group,with statistically significant differences(P<0.05).The level of IL-2 in the combined treatment group was higher than that in the single treatment group,and the level of IL-4 in the combined treatment group was lower than that in the single treatment group,with statistically significant differences(P<0.05).The levels of CD4^(+)and CD4^(+)/CD8^(+)in the combined treatment group were higher than those in the single treatment group,with statistically significant differences(P<0.05).The total incidence of adverse reactions(ADRs)in the combined treatment group was lower than that in the single treatment group,with statistically significant difference(P<0.05).Conclusion Pamidronate disodium combined with compound kushen injection in the treatment of non-small cell lung cancer can regulate the level of inflammatory factors,enhance the antitumor activity and immune function,and reduce the inflammatory reaction,which has low ADRs.

关 键 词：非小细胞肺癌 帕米膦酸二钠 复方苦参注射液 癌胚抗原 糖类抗原125 白介素-2 白介素-4 T淋巴细胞亚群 

分 类 号：R734.2[医药卫生—肿瘤]